Related Experiment Video

Updated: Jun 27, 2026

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice
07:35

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice

Published on: January 26, 2024

Hypoglycaemia in Type 2 diabetes

Simon R Heller1

  • 1Academic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Room OU141, School of Medicine and Biomedical Sciences, Beech Hill Road, Sheffield S10 2RX, UK. s.heller@sheffield.ac.uk

Diabetes Research and Clinical Practice
|December 6, 2008
PubMed

Insights

Hypoglycaemia risk in Type 2 diabetes increases over time as insulin secretion declines. This leads to reduced glucagon and adrenaline responses, impairing the body's ability to manage low blood sugar.

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Diabetes Research

Background:

  • Type 2 diabetes management often involves insulin therapy.
  • Hypoglycaemia (low blood sugar) is a significant concern for all diabetes patients.
  • Physiological responses to hypoglycaemia differ between Type 1 and Type 2 diabetes.

Purpose of the Study:

  • To investigate the long-term risk and physiological mechanisms of hypoglycaemia in Type 2 diabetes patients initiating insulin therapy.
  • To compare the progression of hypoglycaemia counter-regulatory responses in Type 2 diabetes to those in Type 1 diabetes.

Main Methods:

  • Observational study tracking hypoglycaemia rates over time.
  • Assessment of endogenous insulin secretion decline.
  • Evaluation of glucagon and adrenaline responses to low blood sugar.
  • Analysis of sympathoadrenal activation patterns.

Main Results:

  • Initial hypoglycaemia rates are lower in Type 2 diabetes than Type 1 diabetes but increase with time on insulin.
  • Declining endogenous insulin secretion impairs glucagon release.
  • Adrenaline release offers partial compensation but is compromised by recurrent hypoglycaemia.
  • Diminished sympathoadrenal activation eventually mirrors Type 1 diabetes protective failure.

Conclusions:

  • Type 2 diabetes patients on insulin face an escalating risk of hypoglycaemia.
  • Progressive loss of endogenous insulin function compromises crucial counter-regulatory hormonal responses.
  • Long-term insulin use in Type 2 diabetes can lead to similar physiological vulnerabilities as seen in Type 1 diabetes.

More Related Videos

Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Related Concept Videos

Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...